This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Small-Cap Winners & Losers

Smith & Wollensky (SWRG) ballooned 45% after Landry's (LNY) offered to buy the New York-based restaurant operator for $7.50 a share. Smith & Wollensky shares were gaining $2.28 to $7.31. Landry's was up 26 cents, or 0.9%, to $30.45.

Zevex International (ZVXI) surged after the Salt Lake City-based medical equipment maker agreed to be bought by Moog (MOG.A - Get Report) for $13 a share, with an $83.8 million maximum purchase price. The transaction will likely close in March. Zevex shares were trading up $3.40, or 36.3%, to $12.77. Moog was dipping 4 cents to $37.81.

Sinovac Biotech's (SVA - Get Report) fourth-quarter sales soared 56.8% to $6.27 million, the China-based company said, and full-year revenue rose to $15.4 million, up 78.7%. The company attributed these gains to growing demand for its hepatitis A vaccine, Healive. Shares were rising 40 cents, or 17%, to $2.80.

FX Energy (FXEN - Get Report) gained on word that its Winna Gora test well, located in central Poland, yielded gas flow in Rotliegendes-aged sandstone at a depth of about 3,500 meters. Shares of the company were up 99 cents, or 16.8%, to $6.89.

XTL Biopharmaceuticals (XTLB) jumped after the New York-based company inked a deal with Dov Pharmaceutical to develop Dov's Bicifadine drug, which treats neuropathic pain. XTL will pay Dov potential fees in excess of $134 million, including $7.5 million cash upfront, milestone payments of $126.5 million in stock or cash, and royalties. Shares were climbing 58 cents, or 17%, to $3.98.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
FXEN $1.06 0.95%
INWK $6.76 1.80%
MOG.A $57.31 2.00%
SVA $5.13 0.79%
XTLB $1.70 2.41%


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs